ASLAN Pharmaceuticals Announces First Patient Screened in Study of Eblasakimab in Dupilumab Experienced Atopic Dermatitis Patients

• The TRials with EblasaKimab in Dupilumab eXperienced atopic dermatitis patients (TREK-DX) study will evaluate eblasakimab in a patient population with few safe treatment options
• The study will enroll 75 patients in North America with topline results expected in the first quarter of 2024
• Study is fully funded with no impact on previously reported cash runway
• Data from TREK-DX and TREK-AD could support the use of eblasakimab for both biologic naïve and experienced AD patients

Excerpt from the Press Release:

SAN MATEO, Calif. and SINGAPORE, Dec. 15, 2022 (GLOBE NEWSWIRE) — ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that it has screened the first patient in its TREK-DX study of eblasakimab in adult patients with moderate-to-severe atopic dermatitis (AD) who have previously been treated with dupilumab. Eblasakimab is a potential first-in-class monoclonal antibody targeting the IL-13 receptor that has the potential to deliver a differentiated efficacy and safety profile.

The randomized, double-blind, placebo-controlled, Phase 2 clinical trial is expected to enroll 75 patients in North America and will assess the efficacy and safety of eblasakimab in dupilumab experienced patients who have discontinued their treatment for any reason, including inadequate disease control, loss of access to drug or an adverse event. TREK-DX will enable ASLAN to test a once-weekly dosing regimen of 400mg of eblasakimab, which has previously been shown to be safe and well-tolerated in Phase 1 studies that may be the most effective option to address the severity and refractory nature of the disease that these patients experience. It is thought that eblasakimab, with a unique mechanism of action blocking the IL-13 receptor directly and therefore providing complete but specific blockade of the Type 2 receptor, could show benefit in patients who have discontinued treatment with dupilumab.

TREK-DX will provide support to TREK-AD, a trial that is investigating eblasakimab in biologic naïve patients, and could help to strengthen the positioning of eblasakimab as the biologic of first choice for AD treatment. Topline data from TREK-DX is expected in the first quarter of 2024.

Click the button below to read the entire Press Release:

Continue Reading The Press Release